Abstract 1587
Background
The characteristics of elderly patients with IDH-mutant (IDHm) high-grade gliomas (HGG) remain to be described. This study aims to describe characteristics and patterns of care of elderly patients with IDHm HGG included in the French POLA network dedicated to HGG.
Methods
The characteristics and patterns of care of elderly (≥70 years) patients IDHm HGG were compared to those of younger patients (<70 years) with IDHm gliomas and to those of elderly patients with IDH wild-type (IDHwt) gliomas.
Results
Out of the 1433 HGG patients included, 119 (8.3%) occurred in elderly patients. Histology consisted of 1p/19q codeleted anaplastic oligodendroglioma (71.8%), anaplastic IDHm astrocytomas (12.8%) and IDHm glioblastoma (15.4%). Median age at diagnosis was 74 years (70.2-87.1), median Karnofsky Performans Status (KPS) was 80 (50-100). Treatments consisted of a wait and scan policy (7.7%), radiotherapy (RT) alone (7.7%), chemotherapy (CT) alone (41%), RT-CT (RT-TMZ: 25.6%, RT-PCV: 15.4%) or palliative care (2.6%). The clinical, radiological and histological presentations of elderly patients IDHm HGG were different from those of elderly patients IDHwt HGG. Compared to elderly patients IDHwt HGG, elderly patients IDHm were less frequently associated with cognitive impairment (p = 0.045), contrast enhancement (p = 0.01) and had a lower proliferative index (Ki67) (p = 0.005). In contrast, there was no difference regarding clinical, radiological and histological presentations of elderly and younger patients IDHm HGG but their management was different. Elderly patients IDHm less frequently underwent gross total resection (p = 0.002) and radiotherapy (p < 0.001). The median progression-free survival (PFS) and overall survival (OS) were longer for IDHm elderly patients (29.2 and 62.1 months respectively) than IDHwt elderly patients (8.2 and 13.2 months respectively) but shorter than younger IDHm patients (69 months and not reached respectively).
Conclusions
IDHm HGG in elderly show prolonged survival. However, their poorer outcome compared to younger IDHm gliomas may results from patient or tumor characteristics or from under-treatment, suggesting a role for geriatric assessment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
French POLA network.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2990 - Circulating PD-L1 levels vary across brain tumor entities and are oppositely linked to survival in glioblastoma and lower grade glioma patients
Presenter: Maximilian Mair
Session: Poster Discussion – CNS tumours
Resources:
Abstract
1774 - Characterization of a novel BBB-permeable mutant IDH1 inhibitor, DS-1001b.
Presenter: Hironori Matsunaga
Session: Poster Discussion – CNS tumours
Resources:
Abstract
3522 - Precision medicine for patients with primary brain tumors: Molecular Screening for Cancer Treatment Optimization (MOSCATO) prospective trial
Presenter: Wafa Boulfoul
Session: Poster Discussion – CNS tumours
Resources:
Abstract
4589 - Extending temozolomide longer than six cycles in glioblastoma: results of the randomized GEINO-014 TRIAL.
Presenter: Maria Angeles Salgado
Session: Poster Discussion – CNS tumours
Resources:
Abstract
3553 - Association of systemic inflammation with local tumor characteristics and survival in glioma patients
Presenter: Pegah Mir Seyed Nazari
Session: Poster Discussion – CNS tumours
Resources:
Abstract
3418 - GEINO 1402: A Phase Ib Dose-Escalation Study Followed by an Extension Phase to Evaluate Safety and Efficacy of Crizotinib in Combination with Temozolomide (TMZ) and Radiotherapy (RT) in Patients with Newly Diagnosed Glioblastoma (GB)
Presenter: Maria Martinez Garcia
Session: Poster Discussion – CNS tumours
Resources:
Abstract
3331 - Impact of neurological symptom burden on the survival prognosis in a real-life cohort of patients with non-small cell lung cancer brain metastases
Presenter: Ariane Steindl
Session: Poster Discussion – CNS tumours
Resources:
Abstract
3348 - Tumor mutational burden and immune infiltrates in primary renal cell carcinoma and matched brain metastases
Presenter: Ariane Steindl
Session: Poster Discussion – CNS tumours
Resources:
Abstract
Poster Discussion – CNS tumours - Invited Discussant 395PD, 396PD and 397PD
Presenter: Olivier Chinot
Session: Poster Discussion – CNS tumours
Resources:
Slides
Webcast
Poster Discussion – CNS tumours - Invited Discussant 402PD and 403PD
Presenter: Dieta Brandsma
Session: Poster Discussion – CNS tumours
Resources:
Slides
Webcast